stevanato group

Founded in 1949, Stevanato Group is one of the world's largest providers of integrated containment and delivery solutions for the biopharmaceutical industry. From the beginning, the Group has developed its own glass forming technology to ensure quality of the highest standards. The Group includes a wide range of skills dedicated to serving the biopharmaceutical and diagnostic industry. It offers glass containers with its historic Ompi brand, plastic components for diagnostics and medical devices, contract manufacturing services for drug delivery systems, up to inspection, assembly and packaging machines. The Group also provides analytical services and tests that study the interaction between container and drug and integration into delivery sys-tems, supporting the drug development process. By bringing together several skills under the same entity, Stevanato Group is able to offer unique solutions to companies by reducing the time to market and the overall cost.

Mensa Group

The group of companies that is today known as MENSA GROUP started through the establishment of PT Menjangan Sakti by its founder – Mr. Jimmy Sudharta in April 1975. The company started its business by trading pharmaceutical raw materials throughout Indonesia. With time the company expanded its business and diversified its activity to include the cosmetic, food and feed industries. Continuous growth of PT Menjangan Sakti has provided the company the ability and resources to expand into related business. Starting 1981, PT Menjangan Sakti acquired several other companies in related activity including pharmaceutical manufacturing companies and Distribution Company, forming what is today known as Mensa Group. Mensa Group comprises of several companies with diversified activity such as: - importing and trading pharmaceutical raw materials including food, feed and cosmetics; - pharmaceutical manufacturing ; - medical supplies and dental equipment manufacturing; - Pharmaceutical, hospital / medical supplies and consumer goods distribution. The group employs approximately 5000 employees, and main aim in the near future is to establish a solid synergy between the companies and amongst other to develop a nationwide distribution network as an asset for further growth.

Dexa Medica (Member of Dexa Group)

Dexa Medica has evolved from a small company established in 1969 to one of Indonesia’s largest ethical pharmaceutical companies at the beginning of the 21st century and has become a prominent, well-respected player in the domestic pharmaceutical market. Providing better health care by applying expertise was the foundation on which its founders built this Company. Honesty, trust, dedication and commitment to providing patients with the highest quality of ethical pharmaceutical products and OTC are preserved as the guiding principles, based upon which the highly professional management team and the motivated, competent staff of Dexa have developed the Company in the spirit of mutual respect, teamwork and innovation over more than four decades. Serving as a good corporate citizen is one of our responsibilities and being a strategic asset of Indonesia is one of our foremost desires. For along time Dexa has worked together with governing institutions and the Indonesian Pharmaceutical Association – championing compliance and improving the industry standards. Ir. Ferry A. Soetikno, M.Sc., M.B.A. (President Director) ------------------------ Dexa Medica is always on the lookout for talented individuals who want to grow with us. If you are interested in becoming part of our team, please visit our career site at www.dexagroupcareer.com or follow us on Instagram @dexagroupofficial. You can find information about various job opportunities, more details on how to join our team, and glimpses of life at Dexa Group!

Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.

merial

Merial became Boehringer Ingelheim in 2016. This page is no longer active. Please follow the Boehringer Ingelheim page to stay up to date on the latest news: www.linkedin.com/company/boehringer-ingelheim